Statin use and risk of colorectal cancer in a cohort of middle-aged men in the us: A prospective cohort study

Drugs

Volumn 69, Issue 11, 2009, Pages 1445-1457

  Flick, E Dawn ^a,c   Habel, Laurel A ^a   Chan, K Arnold ^c,d   Haque, Reina ^b   Quinn, Virginia P ^b   Van Den Eeden, Stephen K ^a   Sternfeld, Barbara ^a   Orav, Endel J ^e   Seeger, John D ^c,d   Quesenberry Jr , Charles P ^a   Caan, Bette J ^a  

^a DIVISION OF RESEARCH   (United States)

^b Harvard School of Public Health ^*  (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d i3 Drug Safety   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; CERIVASTATIN; DOCOSAHEXAENOIC ACID; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID DERIVATIVE; PRAVASTATIN; PROBUCOL; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; FOLLOW UP; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED;

AGED; CALIFORNIA; COHORT STUDIES; COLORECTAL NEOPLASMS; FOLLOW-UP STUDIES; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK; SOCIOECONOMIC FACTORS;

EID: 67749143897     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-200969110-00004     Document Type: Article

References (49)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta (GA): American Cancer Society, 2007
2. Agarwal B, Halmos B, Feoktistov AS, et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 2002; 23 (3): 521-8
3. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999; 117 (4): 838-47
4. Alonso DF, Farina HG, Skilton G, et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998; 50 (1): 83-93
5. Carlberg M, Dricu A, Blegen H, et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface: evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth. J Biol Chem 1996; 271 (29): 17453-62
6. Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-9
7. Kusama T, Mukai M, Iwasaki T, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-17
8. Lee SJ, Ha MJ, Lee J, et al. Inhibition of the 3-hydroxy-3- methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/ CIP1) in human prostate carcinoma cells. J Biol Chem 1998; 273 (17): 10618-23
9. Matar P, Rozados VR, Roggero EA, et al. Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother Radiopharm 1998; 13 (5): 387-93
10. Muller C, Bockhorn AG, Klusmeier S, et al. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 1998; 12 (3): 717-23
11. Narisawa T, Morotomi M, Fukaura Y, et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996; 87 (8): 798-804
12. Padayatty SJ, Marcelli M, Shao TC, et al. Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endo-crinol Metab 1997; 82: 1434-9
13. Park HJ, Kong D, Iruela-Arispe L, et al. 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91: 143-50
14. Ukomada C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 2003; 278 (44): 43586-94
15. Weis M, Heeschen C, Glassford AJ, et al. Statins have bi-phasic effects on angiogenesis. Circulation 2002; 105 (6): 739-45
16. Wong WW-L, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-19
17. Narisawa T, Fukaura Y, Tanida N, et al. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA re-ductase inhibitor, on 1,2-dimethylhydrazine- induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996; 180 (2): 131-8
18. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev 2005; 14 (8): 1897-8
19. Armitage J, Collins R, Bowman L, et al. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20536 high-risk people: a randomised placebo-controlled trial [ISRCTN484 89393]. Heart Protection Study Collaborative Group. BMC Med 2005; 3: 6
20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
21. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364: 771-7
22. Probstfield JL, Davis BR. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288 (23): 2998-3007
23. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30
24. Simes RJ, Hunt D, Kirby A, et al. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379-87
25. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87 (9): 1074-9
26. Gwyn K, Sinicrope FA. Chemoprevention of colorectal cancer. Am J Gastroenterology 2002; 97 (1): 13-21
27. Wei JT, Mott LA, Baron JA, et al. Reported use of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas. Polyp Prevention Study Group. Cancer Epidemiol Biomarkers Prev 2005; 14: 1026-7
28. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363-8
29. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007; 99: 32-40
30. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643-7
31. Graaf MR, Beiderbeck AB, Egberts ACG, et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22 (12): 2388-94
32. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007; 115: 27-33
33. Vinogradova Y, Hippisley-Cox J, Coupland C, et al. Risk of colorectal cancer in patients prescribed statins, non-steroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007; 133 (2): 393-402
34. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007; 121 (6): 1325-30
35. Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 992184-92
36. Boudreau DM, Koehler E, Rulyak SJ, et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17 (11): 3076-80
37. Jacobs EJ, Rodriguez C, Brady KA, et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006; 98: 69-72
38. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-7
39. Bonovas S, Filioussi K, Flordellis CS, et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25 (23): 3462-8
40. Enger SM, Van den Eeden SK, Sternfeld B, et al. California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health 2006; 6: 172
41. Oehrli MD, Quesenberry Jr CP, Leyden W. Northern California Cancer Registry: 2006 annual report on trends, incidence, and outcomes. Oakland (CA): Kaiser Perma-nente Northern California Cancer Registry, 2006 Nov
42. Haque R, Chiu V, Mehta KR, et al. An automated data algorithm to distinguish screening and diagnostic colo-rectal cancer endoscopy exams. J Natl Cancer Inst Monogr 2005; 35: 116-8
43. Janssen A, Maier TJ, Schiffmann S, et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol 2006; 540 (1-3): 24-33
44. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57 (14): 2909-15
45. Watson AJM. An overview of apoptosis and the prevention of colorectal cancer. Clin Rev Oncol Hematol 2006; 57 (2): 107-21
46. Feleszko W, Jalili A, Olszewska D, et al. Synergistic interaction between highly specific cyclooxygenase-2-inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep 2002; 9 (4): 879-85
47. Reddy BS, Wang CX, Kong AN, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006; 66 (8): 4542-6
48. Setoguchi S, Avorn J, Schneeweiss S. Statins and risk of colorectal cancer. N Engl J Med 2005; 353: 952
49. Selby JV, Smith DH, Johnson ES, et al. Kaiser Permanente medical care program. In: Strom BL, editor. Pharmaco-epidemiology. 4th ed. Chichester: John Wiley & Sons, Ltd, 2005: 241-59